Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
3
×
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
3
×
cancer
3
×
clinical trials
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
3
×
national
national blog main
national top stories
new york blog main
new york top stories
nivolumab
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
3
×
texas top stories
wisconsin blog main
wisconsin top stories
cancer immunotherapy
cell therapy
diagnostics
immunotherapy
investing
medicare
merck
novartis
pembrolizumab keytruda
What
new
3
×
bio
companies
drug
roundup
advantages
approval
bar
biogen’s
biopharmaceutical
biotechs
brings
club
continued
convo
crop
earlier
exceeded
expect
failures
firms
gamble
group
haul
ipo
joined
latest
life
littered
market
medco’s
met
million
momentum
mover
nasdaq
nash
neon
news
offerings
Language
unset
Current search:
new
×
cancer
×
" life sciences "
×
" bristol-myers squibb "
×
" boston top stories "
×
" texas blog main "
×
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M